Eli Lilly's stock rises after its Zepbound weight-loss drug achieved better results than rival Wegovy in a head-to-head trial
Eli Lilly & Co. Inc.'s stock (LLY) rose 2% early Wednesday, after the company said a study comparing its Zepbound weight-loss drug to rival Novo Nordisk's Wegovy showed an average weight loss of 20.2% ...
Why Amgen’s MariTide could rival Eli Lilly, Novo Nordisk’s obesity drugs
Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing ...
This weight loss drug helped people shed more pounds than Wegovy, new trial results show
People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical ...
Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%
Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical ...
Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial
Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of ...
Lilly’s Zepbound Beats Novo’s Wegovy in First Head-to-Head Trial
Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head ...
Trump Can Make Weight-Loss Drugs More Affordable
President Joe Biden wants Medicare and Medicaid to cover weight-loss drugs, a proposal that would expand access to the costly ...
The Root on MSN45mOpinion
[Opinion] 5 Inconvenient Truths About Ozempic, Wegovy and Other Semaglutides, According to Doctors
On Nov. 26, the Biden administration announced a plan to require Medicare and Medicaid to cover weight loss medications like ...
Lilly's Zepbound tops Wegovy for weight loss in head-to-head trial
Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo ...
Eli Lilly’s Zepbound Beats Novo Nordisk’s Wegovy in First Head-to-Head Study
People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s ...
Ibj.com1h
Trial shows Lilly’s Zepbound helps patients lose far more weight than competing drug
Eli Lilly and Co. said its weight-loss treatment Zepbound helped patients lose 47% more relative weight than competitor Novo ...
My patients feel healthier on Ozempic. It's not the best answer for weight loss. | Opinion
Ozempic and Wegovy might be making it harder for physicians to guide patients toward lifestyle changes − the real key to long ...